<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CORTISPORIN- neomycin sulfate, polymyxin b sulfate, bacitracin zinc and hydrocortisone ointment </strong><br>Pfizer Laboratories Div Pfizer Inc<br></p></div>
<h1>CORTISPORIN<span class="Sup">®</span> Ointment<br>(neomycin and polymyxin B sulfates, bacitracin zinc, and hydrocortisone ointment, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_609cb5c7-b21b-48b7-ad66-1653c9d18d31"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">CORTISPORIN Ointment (neomycin and polymyxin B sulfates, bacitracin zinc, and hydrocortisone ointment, USP) is a topical antibacterial ointment. Each gram contains: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 5,000 polymyxin B units, bacitracin zinc equivalent to 400 bacitracin units, hydrocortisone 10 mg (1%), and white petrolatum, qs.</p>
<p>Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of <span class="Italics">Streptomyces fradiae Waksman</span> (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 µg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are:</p>
<p><img alt="ChemStructure1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=097a7a8d-04d4-4736-c8b7-0796117457bf&amp;name=cortisporin-01.jpg"></p>
<p>Polymyxin B sulfate is the sulfate salt of polymyxin B<span class="Sub">1</span> and B<span class="Sub">2</span>, which are produced by the growth of <span class="Italics">Bacillus polymyxa</span> (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are:</p>
<p><img alt="ChemStructure2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=097a7a8d-04d4-4736-c8b7-0796117457bf&amp;name=cortisporin-02.jpg"></p>
<p>Bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin A) produced by the growth of an organism of the <span class="Italics">licheniformis</span> group of <span class="Italics">Bacillus subtilis</span> (Fam. Bacillaceae). It has a potency of not less than 40 bacitracin units per mg. The structural formula is:</p>
<p><img alt="ChemStructure3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=097a7a8d-04d4-4736-c8b7-0796117457bf&amp;name=cortisporin-03.jpg"></p>
<p>Hydrocortisone, 11β,17,21-trihydroxypregn-4-ene-3, 20-dione, is an anti-inflammatory hormone. Its structural formula is:</p>
<p><img alt="ChemStructure4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=097a7a8d-04d4-4736-c8b7-0796117457bf&amp;name=cortisporin-04.jpg"></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_6e1b0285-eef0-4358-a4a5-6f4d037f51ca"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Corticoids suppress the inflammatory response to a variety of agents and they may delay healing. Since corticoids may inhibit the body's defense mechanism against <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.</p>
<p>The anti-infective components in the combination are included to provide action against specific organisms susceptible to them. Polymyxin B sulfate, bacitracin zinc, and neomycin sulfate together are considered active against the following microorganisms: <span class="Italics">Staphylococcus </span>aureus, streptococci, including <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Escherichia coli</span>, <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Klebsiella-Enterobacter</span> species, <span class="Italics">Neisseria </span> species, and <span class="Italics">Pseudomonas</span> aeruginosa.</p>
<p>The product does not provide adequate coverage against <span class="Italics">Serratia marcescens</span>.</p>
<p>The relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_3ecaef70-3b09-4ab3-b2b3-1a3aa18f14c0"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">For the treatment of corticosteroid-responsive dermatoses with <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span>. It has not been demonstrated that this steroid-antibiotic combination provides greater benefit than the steroid component alone after 7 days of treatment. (See <a href="#i4i_warnings_id_0804be1a-630d-4136-96cd-83e3d290e7ba">WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_6b86a075-2c89-4f03-9d72-537603cfaef6"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Not for use in the eyes or in the external ear canal if the eardrum is perforated. This product is contraindicated in tuberculous, fungal, or viral (for example, herpes simplex or <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span>) lesions of the skin. This product is contraindicated in those individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_0804be1a-630d-4136-96cd-83e3d290e7ba"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Neomycin can induce permanent <span class="product-label-link" type="condition" conceptid="374366" conceptname="Sensorineural hearing loss">sensorineural hearing loss</span> due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk of <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> is greater with prolonged use.</p>
<p>Therapy with this product should be limited to 7 days of treatment. (See <a href="#i4i_indications_id_3ecaef70-3b09-4ab3-b2b3-1a3aa18f14c0">INDICATIONS AND USAGE</a>.)</p>
<p>Neomycin sulfate may cause cutaneous sensitization. A precise incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (primarily <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>) due to topical neomycin is not known. Discontinue promptly if sensitization or irritation occurs.</p>
<p>When using neomycin-containing products to control <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span> in the chronic dermatoses, such as chronic <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span> extema or <span class="product-label-link" type="condition" conceptid="4148876" conceptname="Stasis dermatitis">stasis dermatitis</span>, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low-grade reddening with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, dry scaling, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>; it may be manifest simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin-containing applications should be avoided for the patient thereafter.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_bde860d8-bf21-4397-a3f9-04cbf0d2a310"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_f5b55b4c-d77c-409b-a433-f349d33f5a60"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. Treatment should not be continued for longer than 7 days. If the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not improved after 1 week, cultures and susceptibility tests should be repeated to verify the identity of the organism and to determine whether therapy should be changed. Allergic cross-reactions may occur which could prevent the use of any or all of the aminoglycoside antibiotics for the treatment of future <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>Use of steroids on infected areas should be supervised with care as anti-inflammatory steroids may encourage spread of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. If this occurs, steroid therapy should be stopped and appropriate antibacterial drugs used. Generalized dermatological conditions may require systemic corticosteroid therapy.</p>
<p>Signs and symptoms of exogenous <span class="product-label-link" type="condition" conceptid="438123" conceptname="Adrenocortical hyperfunction">hyperadrenocorticism</span> can occur with the use of topical corticosteroids, including adrenal suppression. Systemic absorption of topically applied steroids will be increased if extensive body surface areas are treated or if occlusive dressings are used. Under these circumstances, suitable precautions should be taken when long-term use is anticipated.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_010ce60c-5dd6-4549-9873-e0f9c9a9d88b"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, irritation, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> persists or increases, discontinue use and notify physician. Do not use in the eyes.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_89638e63-a644-4e92-97f4-eb4490749b59"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Systemic effects of excessive levels of hydrocortisone may include a reduction in the number of circulating eosinophils and a decrease in urinary excretion of 17-hydroxycorticosteroids.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_b0441e91-5210-4235-9312-77c8bb6bf000"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis and Mutagenesis and Impairment of Fertility</h2>
<p class="First">Long-term studies in animals (rats, rabbits, mice) showed no evidence of carcinogenicity attributable to oral administration of corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_5aca5c4f-a83a-4cbd-841b-1b1d5efe46ee"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_78574d23-e997-4df8-a7a1-ffde2e655e34"></a><a name="section-6.5.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Teratogenic Effects</span></span></h3>
<p class="First">Pregnancy Category C. Corticosteroids have been shown to be teratogenic in rabbits when applied topically at concentrations of 0.5% on days 6 to 18 of gestation and in mice when applied topically at a concentration of 15% on days 10 to 13 of gestation. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_f1a86878-1b3a-4a71-8488-6d3f2bc21d18"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Hydrocortisone appears in human milk following oral administration of the drug. Since systemic absorption of hydrocortisone may occur when applied topically, caution should be exercised when CORTISPORIN Ointment is used by a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_5f34ff58-c040-4fba-820e-a89a3c1f290f"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. Sufficient percutaneous absorption of hydrocortisone can occur in infants and children during prolonged use to cause cessation of growth, as well as other signs and symptoms of <span class="product-label-link" type="condition" conceptid="438123" conceptname="Adrenocortical hyperfunction">hyperadrenocorticism</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_9ca22709-a0cd-42ab-ae7d-a36ff607431b"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of Cortisporin Ointment did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_4f135d92-7390-4069-a32f-c3dc2931c030"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Neomycin occasionally causes skin sensitization. <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> have also been reported. (See <a href="#i4i_warnings_id_0804be1a-630d-4136-96cd-83e3d290e7ba">WARNINGS</a>.) Adverse reactions have occurred with topical use of antibiotic combinations including neomycin, bacitracin, and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reactions</span> occurred in two of 2,175 (0.09%) individuals in the general population.<span class="Sup">1</span> In another study, the incidence was found to be approximately 1%.<span class="Sup">2</span></p>
<p>The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, irritation, dryness, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">acneiform eruptions</span>, hypopigmentation, <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">perioral dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span>, maceration of the skin, <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span>, <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">skin atrophy</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, and <span class="product-label-link" type="condition" conceptid="4273714" conceptname="Miliaria">miliaria</span>.</p>
<p>When steroid preparations are used for long periods of time in intertriginous areas or over extensive body areas, with or without occlusive non-permeable dressings, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span> may occur; also there exists the possibility of systemic side effects when steroid preparations are used over large areas or for a long period of time.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_2e72d20f-6c90-465f-85f0-e20eacc629c1"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Therapy with this product should be limited to 7 days. A thin film is applied 2 to 4 times daily to the affected area.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_c85af68b-fe9e-4303-9996-c67302a6e141"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Tube of 1/2 oz with applicator tip (<span class="Bold">NDC</span> 61570-031-50).</p>
<p><span class="Bold">Store at 15° to 25°C (59° to 77°F).</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_212672a4-88c3-49cb-8ff0-8311d03ba60d"></a><a name="section-10"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Leyden JJ, Kligman AM. <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span> to neomycin sulfate. <span class="Italics">JAMA. </span>1979;242:1276-1278.</li>
<li>Prystowsky SD, Allen AM, Smith RW, et al. Allergic contact <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to nickel, neomycin, ethylenediamine, and benzocaine. <span class="Italics">Arch Dermatol</span>. 1979;115:959-962.</li>
</ol>
<p class="First">Prescribing Information as of September 2003.</p>
<p>Distributed by: Monarch Pharmaceuticals, Inc., Bristol, TN 37620</p>
<p>(A wholly owned subsidiary of King Pharmaceuticals, Inc.) </p>
<p>Manufactured by: King Pharmaceuticals, Inc., Bristol, TN 37620</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_177d0e08-71d2-49a5-a181-353946bc879d"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1/2 oz Tube Label</h1>
<p class="First">NDC 61570-031-50</p>
<p><span class="Bold"><span class="Italics">Pfizer</span><br>Cortisporin</span><span class="Sup">® </span><span class="Bold">Ointment</span><br>(neomycin and polymyxin B sulfates, bacitracin zinc,<br>and hydrocortisone ointment, USP)</p>
<p><span class="Bold">1/2 oz</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1/2 oz Tube Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=097a7a8d-04d4-4736-c8b7-0796117457bf&amp;name=cortisporin-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_ec6b3be7-0876-4af8-b651-3fea18c6d8db"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1/2 oz Tube Carton</h1>
<p class="First">NDC 61570-031-50</p>
<p><span class="Bold"><span class="Italics">Pfizer</span><br>Cortisporin<span class="Sup">® </span>Ointment</span><br>(neomycin and polymyxin B sulfates, bacitracin zinc,<br>and hydrocortisone ointment, USP)</p>
<p><span class="Bold">1/2 oz</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1/2 oz Tube Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=097a7a8d-04d4-4736-c8b7-0796117457bf&amp;name=cortisporin-06.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CORTISPORIN 		
					</strong><br><span class="contentTableReg">neomycin and polymyxin b sulfates, bacitracin zinc, and hydrocortisone ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61570-031</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NEOMYCIN SULFATE</strong> (NEOMYCIN) </td>
<td class="formItem">NEOMYCIN</td>
<td class="formItem">3.5 mg  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>POLYMYXIN B SULFATE</strong> (POLYMYXIN B) </td>
<td class="formItem">POLYMYXIN B</td>
<td class="formItem">5000 [iU]  in 1 g</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BACITRACIN ZINC</strong> (BACITRACIN) </td>
<td class="formItem">BACITRACIN</td>
<td class="formItem">400 [iU]  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCORTISONE</strong> (HYDROCORTISONE) </td>
<td class="formItem">HYDROCORTISONE</td>
<td class="formItem">10 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61570-031-50</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">14.2 g in 1 TUBE, WITH APPLICATOR; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050168</td>
<td class="formItem">04/15/1955</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pfizer Laboratories Div Pfizer Inc
							(134489525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmacia and Upjohn Company</td>
<td class="formItem"></td>
<td class="formItem">829076566</td>
<td class="formItem">ANALYSIS(61570-031), API MANUFACTURE(61570-031)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">UPM Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">032125469</td>
<td class="formItem">ANALYSIS(61570-031), LABEL(61570-031), MANUFACTURE(61570-031), PACK(61570-031)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f19292e9-4b77-40b4-97d4-a0e67e2c73e5</div>
<div>Set id: 097a7a8d-04d4-4736-c8b7-0796117457bf</div>
<div>Version: 6</div>
<div>Effective Time: 20150401</div>
</div>
</div> <div class="DistributorName">Pfizer Laboratories Div Pfizer Inc</div></p>
</body></html>
